Growth in China helps keep Novartis from the patent cliff

Switzerland-based Novartis is one of a number of leading global pharma companies that has reason to worry about the patent cliff: its top-selling product, hypertension drug Diovan, comes off patent in September. However, the company has just…

Get unlimited access to all IAM content